Seamless phase I-II trial design for assessing toxicity and efficacy for targeted agents

Clinical Cancer Research

Volumn 17, Issue 4, 2011, Pages 640-646

  Hoering, Antje ^a   LeBlanc, Mike ^a   Crowley, John ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSTATIC AGENT;

ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; HUMAN; MAXIMUM TOLERATED DOSE; PHASE 1 CLINICAL TRIAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL;

ANIMALS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CYTOSTATIC AGENTS; HUMANS; LOGISTIC MODELS; MAXIMUM TOLERATED DOSE; MODELS, THEORETICAL; MOLECULAR TARGETED THERAPY; RESEARCH DESIGN;

EID: 79951823629     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-1262     Document Type: Article

References (10)

1. Storer BE. Choosing a phase I design. In:Crowley J, Power Ankerst D, editors. Handbook of statistics in clinical oncology. 2nd ed. Boca Raton (FL): CRC Press; 2006. p. 59-75.
2. Thall PF, Cook JD. Dose-finding based on efficacy-toxicity trade offs. Biometrics 2004;60:684-93. (Pubitemid 39181113)
3. Zhang W, Sargent DJ, Mandrekar S. An adaptive dose-finding design incorporating both toxicity and efficacy. Stat Med 2006;25:2365-83. (Pubitemid 44057044)
4. Hunsberger S, Rubinstein LV, Dancey J, Korn EL, et al. Dose escalation trial designs based on a molecularly targeted endpoint. Stat Med 2005;24:2171-81. (Pubitemid 40960214)
5. Jain RK, Lee JJ, Hong D, Markman M, Gong J, Naing A, et al. Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse. Clin Cancer Res 2010;16:1289-97.
6. Hanrahan EO, Heymach JV. Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer. Clin Cancer Res 2007;13:4617s.
7. Liu PY, Moon J, LeBlanc M. Phase II selection designs. Chapter 9. Handbook of statistics in clinical oncology. 2nd ed. Boca Raton (FL): CRC Press; 2006.
8. Yee TW. The VGAM R-Package: vector generalized linear and additive models. 2009.
9. McCullagh P, Nelder JA. Generalized linear models. 2nd ed. London: Chapman & Hall; 1989.
10. Dale JR. Global cross-ratio models for bivariate, discrete, ordered responses. Biometrics 1986;42:909-17. (Pubitemid 17134907)